86 related articles for article (PubMed ID: 8572305)
1. Use of selective tyrosine kinase blockers to monitor growth factor receptor dephosphorylation in intact cells.
Böhmer FD; Böhmer A; Obermeier A; Ullrich A
Anal Biochem; 1995 Jul; 228(2):267-73. PubMed ID: 8572305
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of platelet-derived growth factor and epidermal growth factor receptor signaling events after treatment of cells with specific synthetic inhibitors of tyrosine kinase phosphorylation.
Lipson KE; Pang L; Huber LJ; Chen H; Tsai JM; Hirth P; Gazit A; Levitzki A; McMahon G
J Pharmacol Exp Ther; 1998 May; 285(2):844-52. PubMed ID: 9580635
[TBL] [Abstract][Full Text] [Related]
3. Selective platelet-derived growth factor receptor kinase blockers reverse sis-transformation.
Kovalenko M; Gazit A; Böhmer A; Rorsman C; Rönnstrand L; Heldin CH; Waltenberger J; Böhmer FD; Levitzki A
Cancer Res; 1994 Dec; 54(23):6106-14. PubMed ID: 7954456
[TBL] [Abstract][Full Text] [Related]
4. Protamine inhibits platelet derived growth factor receptor activity but not epidermal growth factor activity.
Huang JS; Nishimura J; Huang SS; Deuel TF
J Cell Biochem; 1984; 26(4):205-20. PubMed ID: 6099364
[TBL] [Abstract][Full Text] [Related]
5. Activation of tyrosine kinases by alpha1A-adrenergic and growth factor receptors in transfected PC12 cells.
Zhong H; Minneman KP
Biochem J; 1999 Dec; 344 Pt 3(Pt 3):889-94. PubMed ID: 10585878
[TBL] [Abstract][Full Text] [Related]
6. Effect of tumor necrosis factor-alpha on the phosphorylation of tyrosine kinase receptors is associated with dynamic alterations in specific protein-tyrosine phosphatases.
Ahmad F; Goldstein BJ
J Cell Biochem; 1997 Jan; 64(1):117-27. PubMed ID: 9015760
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of cell growth: effects of the tyrosine kinase inhibitor CGP 53716.
Major TC; Keiser JA
J Pharmacol Exp Ther; 1997 Oct; 283(1):402-10. PubMed ID: 9336349
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin II stimulates rat astrocyte mitogen-activated protein kinase activity and growth through EGF and PDGF receptor transactivation.
Clark MA; Gonzalez N
Regul Pept; 2007 Dec; 144(1-3):115-22. PubMed ID: 17688958
[TBL] [Abstract][Full Text] [Related]
9. The platelet-derived-growth-factor receptor, not the epidermal-growth-factor receptor, is used by lysophosphatidic acid to activate p42/44 mitogen-activated protein kinase and to induce prostaglandin G/H synthase-2 in mesangial cells.
Goppelt-Struebe M; Fickel S; Reiser CO
Biochem J; 2000 Jan; 345 Pt 2(Pt 2):217-24. PubMed ID: 10620497
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of inhibition by heparin of PDGF stimulated MAP kinase activation in vascular smooth muscle cells.
Pukac LA; Carter JE; Ottlinger ME; Karnovsky MJ
J Cell Physiol; 1997 Jul; 172(1):69-78. PubMed ID: 9207927
[TBL] [Abstract][Full Text] [Related]
11. In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor.
Panek RL; Lu GH; Klutchko SR; Batley BL; Dahring TK; Hamby JM; Hallak H; Doherty AM; Keiser JA
J Pharmacol Exp Ther; 1997 Dec; 283(3):1433-44. PubMed ID: 9400019
[TBL] [Abstract][Full Text] [Related]
12. Kinase Receptor Activation (KIRA): a rapid and accurate alternative to endpoint bioassays.
Sadick MD
Dev Biol Stand; 1999; 97():121-33. PubMed ID: 10463538
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of phosphotyrosine phosphatases reveals candidate substrates of the PDGF receptor kinase.
Zippel R; Morello L; Brambilla R; Comoglio PM; Alberghina L; Sturani E
Eur J Cell Biol; 1989 Dec; 50(2):428-34. PubMed ID: 2560717
[TBL] [Abstract][Full Text] [Related]
14. Limited selectivity of a synthetic erbstatin derivative for tyrosine kinase and cell growth inhibition.
Treuner M; Böhmer FD; Schulze W; Petuchov SP; Grosse R
Biochem Int; 1992 Mar; 26(4):617-25. PubMed ID: 1319149
[TBL] [Abstract][Full Text] [Related]
15. Dephosphorylation of receptor tyrosine kinases as target of regulation by radiation, oxidants or alkylating agents.
Knebel A; Rahmsdorf HJ; Ullrich A; Herrlich P
EMBO J; 1996 Oct; 15(19):5314-25. PubMed ID: 8895576
[TBL] [Abstract][Full Text] [Related]
16. Expression of human p140trk receptors in p140trk-deficient, PC12/endothelial cells results in nerve growth factor-induced signal transduction and DNA synthesis.
Jiang H; Movsesyan V; Fink DW; Fasler M; Whalin M; Katagiri Y; Monshipouri M; Dickens G; Lelkes PI; Guroff G; Lazarovici P
J Cell Biochem; 1997 Aug; 66(2):229-44. PubMed ID: 9213224
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of growth factor-mediated tyrosine phosphorylation in vascular smooth muscle by PD 089828, a new synthetic protein tyrosine kinase inhibitor.
Dahring TK; Lu GH; Hamby JM; Batley BL; Kraker AJ; Panek RL
J Pharmacol Exp Ther; 1997 Jun; 281(3):1446-56. PubMed ID: 9190882
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms through which gangliosides inhibit PDGF-stimulated mitogenesis in intact Swiss 3T3 cells: receptor tyrosine phosphorylation, intracellular calcium, and receptor binding.
Yates AJ; VanBrocklyn J; Saqr HE; Guan Z; Stokes BT; O'Dorisio MS
Exp Cell Res; 1993 Jan; 204(1):38-45. PubMed ID: 8416794
[TBL] [Abstract][Full Text] [Related]
19. P53 associates with trk tyrosine kinase.
Montano X
Oncogene; 1997 Jul; 15(3):245-56. PubMed ID: 9233759
[TBL] [Abstract][Full Text] [Related]
20. N-Shc: a neural-specific adapter molecule that mediates signaling from neurotrophin/Trk to Ras/MAPK pathway.
Nakamura T; Sanokawa R; Sasaki Y; Ayusawa D; Oishi M; Mori N
Oncogene; 1996 Sep; 13(6):1111-21. PubMed ID: 8808684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
